Canton Strategic Holdings, Inc.

Canton Strategic Holdings, Inc., formerly known as Tharimmune, Inc., is a publicly traded company with a dual focus on clinical-stage biotechnology and a digital asset treasury strategy. Headquartered in Bridgewater, New Jersey, the company's mission is to advance institutional blockchain adoption and the digitization of financial markets through its engagement with the Canton Network, while also developing therapeutic candidates for critical unmet medical needs.

In its biotechnology segment, the company develops a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. Key assets include TH104, a transmucosal film product designed to suppress chronic pruritus in primary biliary cholangitis (PBC) and as a prophylactic countermeasure against high-potency opioids for military personnel and first responders. The pipeline also features early-stage immuno-oncology candidates, such as multi-specific antibodies targeting HER2, HER3, and PD-1 for solid tumors (e.g., TH3215, TH0059, TH1940), and TH023, an oral anti-TNFα monoclonal antibody for autoimmune diseases. Concurrently, the company's digital asset strategy involves the acquisition of Canton Coin, operating as a Super Validator on the Canton Network, and investing in applications that foster institutional utility and adoption of the network across capital markets.

Tharimmune, Inc. rebranded to Canton Strategic Holdings, Inc. on February 18, 2026, with its NASDAQ ticker symbol changing from THAR to CNTN. This strategic pivot followed a significant $545 million private placement in November 2025 to establish its digital asset treasury strategy. The company is positioned as the first publicly traded entity supported by the Canton Foundation, emphasizing its role in advancing institutional blockchain. Recent leadership appointments include Mark Wendland as CEO and Chairman, Angela Radkowski as COO, and Jacob Asbury as CFO, strengthening the team to execute its dual-pronged strategy.